Last reviewed · How we verify
NCT06369662
CD155 Expression in Acute Myeloid Leukemia
trial testing Flow cytometric immunophenotyping in Neoplasms in 93 participants. Completed in 31 May 2024.
31 December 2023
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 93 |
| Start date | 1 July 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 May 2024 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Flow cytometric immunophenotyping
- Complete blood count
- Bone marrow aspiration — full drug profile →
- Cytogenetic testing
- FLT3-ITD using High resolution melting curve (HRM) analysis
Conditions studied
- Neoplasms — all drugs for Neoplasms →
- Hematologic Neoplasms — all drugs for Hematologic Neoplasms →
- Leukemia — all drugs for Leukemia →
- Leukemia, Myeloid — all drugs for Leukemia, Myeloid →
Sponsor
Assiut University
Who can join
Adults 18 to 60, any sex, with Neoplasms or Hematologic Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy. It is the most common form of acute leukemia among adults. In the United States, an estimated 19,940 people will be diagnosed with AML in 2020. CD155 expression was associated with an unfavorable prognosis in solid tumors such as colon cancer, breast cancer, lung adenocarcinoma, pancreatic cancer, melanoma, and glioblastoma, as it correlated with tumor migration, development of metastases, tissue and lymph node invasion, relapse, and poorer survival.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
CD155 as a prognostic and predictive biomarker in acute myeloid leukemia.
Abdalla AZ, Khallaf SM, Zahran AM, Rayan NA, et al · · 2025 · PMID 40411696 · DOI 10.1007/s12672-025-02665-2
Verify or expand the search:
- PubMed search for NCT06369662
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Flow cytometric immunophenotyping
Trials testing the same drug.
- NCT04543149 — Immune Cells in Patients With Granulomatous Mastitis · completed
Other recruiting trials for Neoplasms
Currently open trials in the same condition.
- NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
- NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
- NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
- NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
- NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06369662 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 16 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06369662.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing